CN107007843A - PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes - Google Patents

PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes Download PDF

Info

Publication number
CN107007843A
CN107007843A CN201710126678.8A CN201710126678A CN107007843A CN 107007843 A CN107007843 A CN 107007843A CN 201710126678 A CN201710126678 A CN 201710126678A CN 107007843 A CN107007843 A CN 107007843A
Authority
CN
China
Prior art keywords
spio
nota
peg
preparation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710126678.8A
Other languages
Chinese (zh)
Inventor
尹吉林
王欣璐
吴凡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital of Guangzhou Military Command
Original Assignee
General Hospital of Guangzhou Military Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital of Guangzhou Military Command filed Critical General Hospital of Guangzhou Military Command
Priority to CN201710126678.8A priority Critical patent/CN107007843A/en
Publication of CN107007843A publication Critical patent/CN107007843A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The invention discloses a kind of compound SPIO NOTA68Ga and preparation method thereof, uses polyethyleneglycol derivative (PEG2000) modification SPIO surfaces amino by bifunctional chelating agent Isosorbide-5-Nitrae, 7 three azo-cycle nonane Isosorbide-5-Nitraes, 7 triacetic acids (NOTA) are coupled into Nanosurface, obtain labelled precursor SPIO PEG2000NOTA, is then used68Ga carries out radioactive label to SPIO, obtains SPIO NOTA68Ga.In addition, the invention discloses SPIO NOTA68Ga purposes, by studying its external and part vivo biodistribution property, as a result finds SPIO NOTA68Ga has good physicochemical property and biocompatibility as PET/MRI bimodal probes, and it has higher vitro stability and a good water solubility, and mark rate it is high, without purifying, the research imaged available for follow-up PET/MRI bimodals.

Description

PET/MRI bimodal developers SPIO-NOTA-68Ga and preparation method thereof and purposes
Technical field
The present invention relates to PET/MRI bimodal developers SPIO-NOTA-68Ga and preparation method thereof and purposes, belong to medical science Field.
Background technology
In the clinical diagnosis of tumour, positron emission tomography (positron emission tomography, PET more and more important effect) is played with Magnetic resonance imaging (magnetic resonance imaging, MRI), but it is single The PET and MRI of one pattern have certain limitation in diagnosis, therefore, and PET/MRI integration technology turns into current image The inevitable trend of technology.PET/MRI scanners in 2011 have been enter into clinic, but up to the present do not have yet for clinic Bimodal imaging medicament comes out.So a kind of effective bimodal imaging medicament of design just becomes an important research work Make.A kind of synthesis of new PET/MRI bimodal medicines and preliminary Quality Research are reported herein.
SPIO nano-particle (superparamagnetic iron oxide nanoparticles, SPION the research of medical domain) is widely used in because of excellent magnetic property and good biocompatibility, it is repaiied After decorations, it can will launch the targeted moleculars such as nucleic, the polypeptide of positive electron and be connected thereto face, reach target drug-carrying, MRIT2WI is cloudy Property contrast agent, cell Magnetic Isolation and purify DNA effect.
The content of the invention
A kind of new PET/MRI bimodal probes are provided it is an object of the invention to overcome drawbacks described above, the spy Needle set has good stability and biocompatibility, can be circulated in intravital blood, is provided for the imaging of PET/MRI bimodals good Good basis.
To achieve the above object, the technical scheme taken of the present invention is：A kind of compound SPIO-NOTA-68Ga。
In addition, the invention discloses compound SPIO-NOTA-68Ga preparation method：Using68Ga is to precursor SPIO- PEG2000- NOTA carries out radioactive label, produces compound SPIO-NOTA-68Ga。
68Ga(T1/2=68min, β+=89%, EC=11%) as excellent positron imaging nucleic, its can directly by68Ge/68Prepared by Ga generators, easy to operate, half-life period 68min, blood understands that soon, the radiation that patient is subject to is less,68Ga ions Radius (0.062nm) size is suitable, is adapted to NOTA three azo-cycle part holes, product thermodynamics and power that the two chelating is formed Learn stability higher, can keep complete for a long time in vivo, therefore present inventor uses68Ga carries out radioactivity mark to SPIO Note, obtains compound SPIO-NOTA-68Ga。
It is preferred that, precursor SPIO-PEG2000- NOTA preparation method is：Use PEG2000NOTA is coupled by the SPIO of modification Enter Nanosurface, produce precursor SPIO-PEG2000-NOTA。
Positron radionuclide and MRI contrast agent are combined to form a kind of new imaging by present inventor based on SPIO Probe, it uses polyethyleneglycol derivative (PEG2000) modification SPIO using the amino on surface by bifunctional chelating agent 1,4,7- Three azo-cycle nonanes-Isosorbide-5-Nitrae, 7- triacetic acids (Isosorbide-5-Nitrae, 7-triazacyclononane-1,4,7-triacetic acid, NOTA) are even Nanosurface is connected to, labelled precursor SPIO-PEG is obtained2000-NOTA。
It is preferred that, precursor SPIO-PEG2000- NOTA preparation method comprises the following steps：(1) NOTA-NHS is dissolved in In deionized water, stir and evenly mix, be completely dissolved to NOTA-NHS；(2) by SPIO-PEG2000-NH2It is dissolved in deionized water, adds NaOH adjusts PH to alkalescent；(3) SPIO-PEG for adding the NOTA-NHS dissolved in step (1) in step (2)2000- NH2In solution, heating, ultrasound, reaction end produce precursor SPIO-PEG2000-NOTA。
It is preferred that, NaOH regulations PH to 9.0-10.0 is added in step (2).
It is preferred that, heating-up temperature is 40 DEG C in step (3), and ultrasonic time is 5min.
It is preferred that, precursor SPIO-PEG2000- NOTA preparation method also include step (4) using super filter tube purify, from The heart, that is, obtain pure precursor SPIO-PEG2000-NOTA。
It is preferred that, the size of super filter tube is 30K, and centrifugation time is 24h.
In addition, the invention discloses compound SPIO-NOTA-68Purposes of the Ga in clinical tumor diagnosis.
It is preferred that, SPIO-NOTA-68Purposes of the Ga in the imaging of PET/MRI bimodals.
The beneficial effects of the present invention are：Compound SPIO-NOTA- of the present invention68Ga have very high radiochemicsl purity, Good vitro stability and water solubility, is conducive to SPIO-NOTA-68Blood circulations of the Ga in mouse live body, is intravital Biodistribution provides the foundation.SPIO-NOTA- of the present invention68Ga preparation method, by connecting big ring on SPIO surfaces Part NOTA, successfully synthesizes labelled precursor SPIO-PEG2000- NOTA, and use positron-emitting radionuclides68Ga is carried out to it Mark, this reaction generated time is shorter (10min), and reactions steps are simple, one-step synthesis, mild condition (70 DEG C), and mark Rate is up to 99%, next step experiment is can be used to without being further purified, with the potential quality for being converted into clinical practice.
Brief description of the drawings
Fig. 1 is labelled precursor SPIO-PEG2000- NOTA synthetic route；
Fig. 2 is product SPIO-NOTA-68Ga synthetic route；
Fig. 3 is SPIO-PEG2000Particle diameter and pattern (TEM) figure of-NOTA nano-particles；
Fig. 4 is SPIO-PEG2000-NH2And SPIO-PEG (a)2000- NOTA (b) hydration kinetics diameter distribution profile；
Fig. 5 is SPIO-PEG2000-NH2And SPIO-PEG (a)2000- NOTA (b) Zeta potential figure；
Fig. 6 is SPIO-PEG2000-NH2(a)、SPIO-PEG2000- NOTA (b) infrared spectrogram；
Fig. 7 is SPIO-PEG2000- NOTA hysteresis curve, wherein abscissa are external magnetic field strength, and ordinate is nanoparticle The sub- intensity of magnetization；
Fig. 8 is product SPIO-NOTA-68Ga ITLC collection of illustrative plates；
Fig. 9 is SPIO-NOTA-68Stability of the Ga in PBS and calf serum (FBS) compares figure, when wherein abscissa is Between, ordinate is radiochemical purity；
Figure 10 is SPIO-NOTA-68Ga is in the internal distribution map (n=3) of normal kunming mice, and wherein abscissa is followed successively by Blood, heart, lung, liver, spleen, kidney, stomach, duodenum, pancreas gland, brain, muscle, bone, skin；
Embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment and accompanying drawing pair The present invention is described further.
1. materials and methods
1.1 reagents and instrument
SPIO-PEG2000-NH2(1mg/ml, Nanjing Xian Feng Nono-material Science ＆ Technology Ltd.), NOTA-NHS (France CHEMATECH companies), (the Shanghai lark waffle skill such as watery hydrochloric acid (12.5mol/L, Merck KGaA company) sodium acetate, glacial acetic acid Art Co., Ltd), MEM nutrient solutions, hyclone, 0.25% trypsase, PBS liquid etc. (Gibco companies of the U.S.), normal Kunming Mouse, male, 18~22g (Nanfang Medical Univ's Experimental Animal Center).
JEM-200CX transmission electron microscopes (Japanese JEOL companies), (Britain Malvern is public for NanoZS nano particle sizes potentiometer Department), vibrating specimen magnetometer VSM 7407 (Lakeshore companies of the U.S.), IRAffinity-1 Fourier transform infrared spectroscopies Instrument (Japanese SHIMADAZU companies), germanium-gallium generator (German ITG companies), Radio-TLC (Japanese Shimadzu Corporation), FC- 3200 radiation monitos (Bioscan companies of the U.S.), (Shanghai core institute day ring photoelectric instrument has SN-695 γ radiation immunity arithmometers Limit company), DF-101S heat collecting types constant-temperature heating magnetic stirring apparatus (Yuhua Instrument Co., Ltd., Gongyi City), water-bath (on The grand experimental facilities Co., Ltd DK-S22 types of Nereid)；Electronic balance (Switzerland Mettlertoledo).
1.2 precursor SPIO-PEG2000- NOTA synthesis
Precursor SPIO-PEG2000- NOTA synthetic route is shown in Fig. 1.3mgNOTA-NHS is taken to be dissolved in appropriate amount of deionized water In, stir and evenly mix, treat that NOTA-NHS is completely dissolved；Take magnetic nano particle (SPIO-PEG2000-NH2) 5mg is soluble in water, add NaOH adjusts PH to 9.0；Logical N2, the NOTA-NHS dissolved is added in the nano particle for mixing up PH, heats 40 DEG C, ultrasound point 5min is dissipated, is stirred overnight, reacts and stops after reaction 24h；Purified using super filter tube (30K), centrifuge 24h, obtain labelled precursor SPIO-PEG2000-NOTA。
1.3 fundamental propertys are detected
1.3.1 transmission electron microscope (TEM) is determined：Take appropriate SPIO-PEG2000- NOTA nano-particles are ground, with ethanol Make after dispersant, ultrasonic disperse, take partial suspended liquid to be placed in copper mesh, spontaneously dry, seen using high resolution transmission electron microscopy Survey form, the particle diameter of particle.
1.3.2 dynamic light scattering (DLS) is detected：Take 1% (ω/V) SPIO-PEG2000-NH2And SPIO-PEG2000- The NOTA aqueous solution is added in quartz colorimetric utensil, using 633nm He/Ne laser in NanoZS nano particle size potentiometric analyzer samples Measure is scanned in room.
1.3.3Zeta potential measurement：SPIO-PEG is measured using NanoZS nano particle sizes potentiometric analyzer2000-NH2And SPIO-PEG2000- NOTA current potentials.
1.3.4 magnetometric analysis：Take appropriate SPIO-PEG2000-NH2And SPIO-PEG2000- NOTA loads about 7mm cotton swab pipe In, sealing two ends are tested in vibrating specimen magnetometer (VSM 7407) sample chamber.
1.3.5 Fourier transform infrared spectroscopy (FT-IR) is determined：Take the SPIO-PEG after appropriate freeze2000-NH2And SPIO-PEG2000After-NOTA powder is mixed with KBr respectively, tabletting is ground, is determined in IRAffinity-1 sample chambers.
1.4SPIO-NOTA-68Ga preparation
Product SPIO-NOTA-68Ga synthetic route is shown in Fig. 2.Take the SPIO- that 200 μ lFe concentration are 1mg/ml PEG2000- NOTA adds the 68Ga (148MBq) that 500 μ l0.05N watery hydrochloric acid are eluted in the small reaction bulbs of 2ml, then adds Enter 32.5 μ l sodium acetates (1mol/L), after being vortexed uniformly, 10min is reacted under the conditions of 70 DEG C, mark is completed.
The measure of 1.5 mark rates
Mark rate is determined using instant thin-layer chromatography method (ITLC).Take 2 μ l react liquid spotting in ITLC-SG paper (10mm × On 150mm), the ascending development in ultra-pure water dries in air naturally.It is scanned with Bioscan radio thin layer's scanners, Calculate mark rate (%).
1.6 estimation of stability
100ul reaction solutions are taken, 500 μ l calf serum and 500 μ l PBS (pH=7.24,0.02mol/ is added separately to L in).Incubation 0.5,1,1.5,2h in 37 DEG C of water bath are placed in, takes about 2ul sample ITLC methods to survey respectively at different time points Its fixed radiochemicsl purity, in triplicate, averages.
1.7 lipids are determined
10 μ l reaction solutions are taken, (containing 500 μ l n-octyl alcohols and 500 μ l PBS), to be sealed in 1.5ml centrifuge tubes with glued membrane respectively, After abundant vortex 2min, high speed centrifugation 3min (10000rpm/min), to biphase equilibrium.It is each from organic phase and aqueous phase with liquid-transfering gun Sample 10 μ l to be placed in two V counter tubes, measure its radiocounting.Lipid (logP) is calculated as follows.Weight It is measured by sampling 3 times, averages again.
LogP=log (cts n-octyl alcohols/cts PBS), wherein, cts n-octyl alcohols and cts PBS are respectively n-octyl alcohol and PBS In γ count.
Bio distribution in 1.8 normal mouse bodies
100 μ l reaction solutions (7.4MBq) are taken respectively, are entered through tail vein injection in 12 Kunming mouse bodies, respectively at after injection After 5min, 30min, 60min, 120min eyeball venous blood sampling, disconnected neck is put to death and dissected, take respectively blood, heart, lung, liver, The organ or tissues such as spleen, kidney, stomach, small intestine, pancreas, brain, muscle, bone, skin, are weighed, and γ is counted, after correction for attenuation Determine the percentage injection dose rate (%ID/g) of its per gram of tissue.
1.9 interpretations of result and processing statistical analysis application SPSS13.0 software kits, continuous data mean ± standard deviationRepresent, figure is made using GraphPad Prism 5.0 and obtained.
2. conclusion
2.1 precursor SPIO-PEG2000- NOTA synthesized reference JarrettBR report, by the SPIO- of design PEG2000-NH2A large amount of amino are contained in end, and it enters with the carbonyl (dissociateing free carboxy under alkalescence condition) on NOTA-NHS esters Row reaction, as shown in Fig. 1 red lines, obtains precursor SPIO-PEG2000-NOTA.This reactions steps is simple, mild condition, quick, high Effect.
2.2 basic characterize are detected
2.2.1 precursor SPIO-PEG2000- NOTA is dissolved in ultra-pure water, is light brown clear solution.
2.2.2 precursor SPIO-PEG2000- NOTA transmission electron microscopes (TEM) image be shown under Fig. 3, Electronic Speculum nanometer particle size be 8~ 12nm or so, it is spherical in shape, it is uniform in size, disperse homogeneous.
2.2.3DLS before analysis result such as Fig. 4, connection NOTA the DLS figures of (a) and (b) afterwards be illustrated as it is unimodal, before connection Darwin's particle diameter of nanometer about 34nm and 89nm respectively, is connected into after NOTA, Darwin's particle diameter is significantly increased afterwards, and distribution compared with It is narrow.
2.2.4Zeta current potential result such as Fig. 5, is connected (a) and rear (b) before NOTA, because a large amount of amino of Nanosurface are carboxylic Base is replaced, and current potential forms upset (11.6mV~-29mV).
2.2.5 infrared spectrum (curve b) 1632.2cm after infrared detections such as Fig. 6, NOTA modification-1Place is (red in Fig. 6 b Line) occur in that new absworption peak, it is considered to it is by newly forming the N-H flexural vibrations in amido link in NH-CO and C-N stretching vibration Interact and produce.
2.2.6 magnetometric analysis result such as Fig. 7, magnetic hysteresis loop shows, increases with external magnetic field strength, the nano-particle intensity of magnetization Increase, when additional magnetic intensity reaches certain value (2000Oe), magnetic intensity speedup tends to be slow, gradually up to magnetic saturation state.SPIO- PEG2000- NOTA specific saturation magnetizations are 56.04emu/g, with good superparamagnetism, point out this precursor can be as MRI The potentiality of developer.
2.3 mark rates are determined
Marked product SPIO-NOTA-68After Ga is separated through ITLC, detected, as a result such as Fig. 8, shown with thin layer radioactive scanning instrument Show in this expansion system, SPIO-NOTA-68Ga is retained in origin nearby (Rf is 0~0.1), free68Ga ions are with solvent Chromatographic paper forward position is moved to, its Rf is 0.8~1.0, and it is about 99% that system automatic integration, which measures its mark rate,.
2.4 estimation of stability
In the environment of 37 DEG C, product SPIO-NOTA-68Ga is incubated 0.5 respectively in PBS and FBS, 1,1.5, after 2h, use Radio-TLC determines its radiochemical purity, as a result sees Fig. 9.Known by figure, until 120min, SPIO-NOTA-68Ga no matter Good stability is respectively provided with PBS or FBS, radiochemicsl purity shows that it has good stabilization in vitro more than 95% Property
2.5 lipid
SPIO-NOTA-68Ga lipid log P=-2.60 ± 0.13 (n=3), shows as hydrophily.This with Its surface modification has a large amount of PEG relevant, and its water-wet behavior can improve the distribution operating of nanometer in vivo, during extension body-internal-circulation Between.
Biodistribution in 2.6 normal mouse bodies
SPIO-NOTA-68Ga is shown in Figure 10 and table 1 in normal kunming mice vivo biodistribution distributed data, as a result shows SPIO- NOTA-68Ga is mainly liver and spleen intake, and with time lengthening, intake is increased, and 120min reaches highest.Rarely seen a small amount of radiation in kidney Property accumulation, with time lengthening, radioactivity substantially lowers.Probe in blood clean up speed quickly, with time lengthening, in blood Radioactivity substantially lower.Obvious intake is showed no in other organs.
The SPIO-NOTA- of table 168Internal distribution results of the Ga in normal kunming mice
3. Analysis of conclusion
This experiment is prepared for the labelled precursor SPIO-PEG of excellent aqueous solubility2000-NOTA.Pass through the means table such as TEM, DLS Levy, show the precursor pattern prepared preferably, good dispersion, particle diameter is small and homogeneous, the SPIO-PEG that this experiment is measured2000-NOTA TEM particle diameters for 10nm or so, DLS particle diameters reach 89nm, and it is consistent with document description, and what is measured mainly due to Electronic Speculum is granular core Heart particle diameter, and the measurement of nano particle size instrument is hydration particle diameter, contains the water-soluble coating of nanometer outer layer.Relaxation rate test shows The nano particle of gained has higher r2 relaxation rates, can be used as the good platform for building PET/MRI bimodal developers.Shi Xudong Etc. using64Cu is marked to SPIO-DOPA-PEG-DOTA/RGD, has obtained PET/MRI bimodal probe, but it is marked Note rate is relatively low, and only 71%, it is necessary to which DTPA is further purified；Madru R are used99TcmSPIO is marked, is obtained SPECT/MRI bimodals probes is used for lymph node imaging；It is rare to use68Ga marks SPIO report, and this research is used68Ga marks SPIO obtains SPIO-NOTA-68Ga, this reaction generated time is shorter (10min), and reactions steps are simple, and a step is closed Into, mild condition (70 DEG C), and mark rate is up to 99%, next step experiment is can be used to without being further purified, with conversion For the potential quality of clinical practice.
SPIO-NOTA-68Ga is demonstrated by very high radiochemicsl purity in PBS and FBS, shows that it has well external Stability, is that further vivo biodistribution evaluation is had laid a good foundation.PEG is modified with because this receives detecting probe surface, its Surface hydrophilic, kernel lipophilic, good water solubility and biocompatibility are conducive to blood circulation of the nanometer in mouse live body, are Intravital biodistribution provides the foundation.
Distribution is shown in normal mouse body, radioactive uptake highest ((31.87 ± 2.89) %ID/g) in 5min in blood, Decline rapidly with time lengthening, during 30min reach ((2.85 ± 0.82) %ID/g), 120min be down to ((1.83 ± 0.72) %ID/g) show that it is cleaned up rapidly in blood；Radioactively labelled substance is mainly gathered in liver and spleen, and prolongs with the time Long, radioactive uptake is further raised, and 120min reaches highest, and liver is ((68.00 ± 7.78) %ID/g), and spleen is ((52.24 ± 8.32) %ID/g)；And the intake of other organs is relatively low, show that the label is mainly metabolized by liver, spleen. Bio distribution and metabolic pathway are basically identical in this nanometer body with particle diameter ＜ 100nm.Reticuloendothelial system (RES, including liver Dirty, spleen, lung and myeloid tissue) containing abundant macrophage, the nanometer of particular size can be swallowed as foreign matter, be retained in liver and spleen Deng in internal organs.100~200nm of LaurentS report particle diameters particle is clear by the macrophage phagocytosis of reticuloendothelial system quickly Remove, in the lysosome for reaching Kupffer Schwann Cells；50~100nm of particle diameter particles can enter liver parenchyma, then main point of ＜ 50nm It is distributed in spleen and marrow, SPIO-NOTA- in the present invention68Ga particle diameter is about 89nm, therefore mainly by liver, splenic uptake.
4. conclusion
By connecting macrocyclic ligand NOTA on SPIO surfaces, labelled precursor SPIO-PEG is successfully synthesized2000- NOTA, and Use positron-emitting radionuclides68Ga is marked to it, reaction time 10min, 70 DEG C of reaction temperature, and mark rate is reachable 99%.The label has higher vitro stability and with good water solubility.Biodistribution in normal mouse body Disclose it to be mainly metabolized by liver and spleen, imaged available for follow-up PET/MRI bimodals.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than the present invention is protected The limitation of scope is protected, although being explained in detail with reference to preferred embodiment to the present invention, one of ordinary skill in the art should Understand, technical scheme can be modified or equivalent substitution, without departing from the essence of technical solution of the present invention.

Claims (10)

1. a kind of compound SPIO-NOTA-68Ga。
2. a kind of preparation method of compound as claimed in claim 1, it is characterised in that use68Ga is to precursor SPIO- PEG2000- NOTA carries out radioactive label, produces compound SPIO-NOTA-68Ga。
3. the preparation method of compound as claimed in claim 2, it is characterised in that the precursor SPIO-PEG2000- NOTA system Preparation Method is：Use PEG2000NOTA is coupled into Nanosurface by the SPIO of modification, produces precursor SPIO-PEG2000-NOTA。
4. the preparation method of compound as described in Claims 2 or 3, it is characterised in that the precursor SPIO-PEG2000- NOTA's Preparation method comprises the following steps：(1) NOTA-NHS is dissolved in deionized water, stirred and evenly mixed, it is completely molten to NOTA-NHS Solution；(2) by SPIO-PEG2000-NH2It is dissolved in deionized water, adds NaOH and adjust PH to alkalescent；(3) will be molten in step (1) The SPIO-PEG that the NOTA-NHS solved is added in step (2)2000-NH2In solution, heating, ultrasound, reaction end produce precursor SPIO-PEG2000-NOTA。
5. the preparation method of compound as claimed in claim 4, it is characterised in that NaOH regulations PH is added in the step (2) To 9.0-10.0.
6. the preparation method of compound as claimed in claim 4, it is characterised in that heating-up temperature is 40 DEG C in the step (3), Ultrasonic time is 5min.
7. the preparation method of compound as claimed in claim 4, it is characterised in that the precursor SPIO-PEG2000- NOTA system Preparation Method is also included step (4) and is purified, centrifuged using super filter tube, that is, obtains pure precursor SPIO-PEG2000-NOTA。
8. the preparation method of compound as claimed in claim 7, it is characterised in that the size of the super filter tube is 30K, during centrifugation Between be 24h.
9. purposes of the compound as claimed in claim 1 in clinical tumor diagnosis.
10. purposes as claimed in claim 9, it is characterised in that the SPIO-NOTA-68Ga is imaged in PET/MRI bimodals In purposes.
CN201710126678.8A 2017-03-03 2017-03-03 PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes Pending CN107007843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710126678.8A CN107007843A (en) 2017-03-03 2017-03-03 PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710126678.8A CN107007843A (en) 2017-03-03 2017-03-03 PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes

Publications (1)

Publication Number Publication Date
CN107007843A true CN107007843A (en) 2017-08-04

Family

ID=59439777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710126678.8A Pending CN107007843A (en) 2017-03-03 2017-03-03 PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes

Country Status (1)

Country Link
CN (1) CN107007843A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102167813A (en) * 2011-01-19 2011-08-31 兰州大学 Fluorescent tracing nanometer magnetic resonance imaging contrast agent
CN102614536A (en) * 2012-03-31 2012-08-01 南京市第一医院 Cell apoptosis imaging medicament 68Ga-NOTA-Duramycin and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102167813A (en) * 2011-01-19 2011-08-31 兰州大学 Fluorescent tracing nanometer magnetic resonance imaging contrast agent
CN102614536A (en) * 2012-03-31 2012-08-01 南京市第一医院 Cell apoptosis imaging medicament 68Ga-NOTA-Duramycin and preparation method thereof

Similar Documents

Publication Publication Date Title
Yang et al. Affibody modified and radiolabeled gold–iron oxide hetero-nanostructures for tumor PET, optical and MR imaging
Hou et al. Nanodiamond–Manganese dual mode MRI contrast agents for enhanced liver tumor detection
CA2195318C (en) Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
Guo et al. pH-sensitive radiolabeled and superfluorinated ultra-small palladium nanosheet as a high-performance multimodal platform for tumor theranostics
CN101912623B (en) Preparation and application of Fe-Gd double-mode magnetic resonance contrast agent with targeting function
Burke et al. Final step gallium-68 radiolabelling of silica-coated iron oxide nanorods as potential PET/MR multimodal imaging agents
Jung et al. MRI of transplanted surface-labeled pancreatic islets with heparinized superparamagnetic iron oxide nanoparticles
CN104436220B (en) A kind of preparation method and its usage of chitosan magnetic Nano microsphere
Wu et al. Reduction-active Fe3O4-loaded micelles with aggregation-enhanced MRI contrast for differential diagnosis of Neroglioma
Xia et al. Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer
CN103143043A (en) Preparation method of Fe3O4/Au composite nanoparticles
Sun et al. Robust surface coating for a fast, facile fluorine-18 labeling of iron oxide nanoparticles for PET/MR dual-modality imaging
BR112019023725A2 (en) BILIRUBIN DERIVATIVE PARTICLE, USE OF THE SAME, COMPOSITION, AND, METHOD FOR PREPARING A BILIRUBIN DERIVATIVE PARTICLE
CN107281504A (en) A kind of preparation method of the SPECT/CT bimodal image-forming contrast mediums based on second generation polyamide-amine dendrimer
CN105079826A (en) Preparation method and application of RGD@BBN double-targeted MR (magnetic resonance)/optical dual-mode molecular probe
CN104225630B (en) Multi-mode self-assembly nanoprobe suitable for MRI (magnetic resonance imaging)/PA (optical activation) and other imaging
Ma et al. Three-dimensional angiography fused with CT/MRI for multimodal imaging of nanoparticles based on Ba 4 Yb 3 F 17: Lu 3+, Gd 3+
CN105412950A (en) Tumor-targeted multifunctional nano probe with MRI (Magnetic Resonance Imaging)/SPECT (Single Photon Emission Computed Tomography) bimodal images as well as preparation method and application thereof
CN107343961A (en) A kind of preparation method of the hyperbranched polyethyleneimine nano-probe based on rgd peptide modification
CN113797361A (en) Active targeting PET/MR bimodal imaging nanoprobe and preparation method thereof
Zhang et al. Preparation and MRI performances of core-shell structural PEG salicylic acid-gadolinium composite nanoparticles
CN109865145B (en) Preparation method of radionuclide 131I-labeled functionalized polyphosphazene nanospheres
CN107096044A (en) Nuclear medicine and magnetic resonance bimodal imaging medicament, prodrug, preparation method and application
Fan et al. The distribution and imaging of 99mTc-nGO-PEG-FA in human Patu8988 tumor-bearing nude mice
CN107007843A (en) PET/MRI bimodal developer SPIO NOTA68Ga and preparation method thereof and purposes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170804

WD01 Invention patent application deemed withdrawn after publication